(CNBC) For the average hedge fund, 2015 was nothing to brag about, and even may have proved humiliating. But a handful of portfolio managers outperformed their peers by a big margin, largely thanks to smart stock picking and shorting in areas like consumer stocks and biotech names.
One of the very best performances — about 47 percent upside apiece, according to investors in both funds — was shared by a pair of hedge funds: Melvin Capital, the roughly $1.5 billion hedge fund run by SAC Capital alumnus Gabriel Plotkin, and Perceptive Life Sciences, the $1.5 billion fund run by veteran biotech investor Joe Edelman.
